Medical Reprints Deployment on iPads and Websites Made Easier

Reprints Desk, Inc., a Derycz Scientific (OTC.BB:DYSC) company, today announced the launch and first sale of its new mobile-web application Article Viewer for deploying medical reprints on iPads, mobile devices, product websites, and portals for healthcare professionals (HCPs) and patients. Reprints Desk specifically designed Article Viewer for use by companies in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics, as well as Scientific Publishing.

Article Viewer is powered by a content management console that enables authorized administrators to efficiently load and deploy article eprints, then access on-demand usage analytics. Users with iPads can access the content they need by downloading the free Article Viewer mobile app from Apple’s App Store, then load articles they have licensed for anytime-anywhere access. Users can also access article eprints, both single eprints and collections of eprints, via a sleek interface on the web. Articles remain accessible according to license agreements secured with rights holders.

“Article Viewer solves the most painful eprint deployment challenges for Life Science companies and publishers, balancing the accessibility needs of users with controls for protecting copyrighted materials,” said Peter Derycz, President and CEO at Reprints Desk. “Whether your company needs an app or has its own, Article Viewer make it easier to integrate licensed eprints into field sales, meetings, and multichannel marketing.”

Scholarly, peer-reviewed journal articles known as ‘clinical reprints’ are important educational tools for healthcare professionals, helping them to understand new therapies and stay current on changing standards of care. HCPs access journal articles through subscriptions and libraries, discovery tools such as PubMed, alerting services, and through the sales, marketing, and medical affairs channels of Life Science companies. Reprints Desk provides software and services to improve enterprise reprints acquisition and deployment, both for eprints and professionally printed reprints.

For more information about Reprints Desk, visit the company’s website online at www.reprintsdesk.com.    


About Reprints Desk®
Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions and scientific, technical, and medical (STM) research. Organizations based on intellectual property (IP) choose Reprints Desk because of its collaborative business approach, efficient article supply system and services, and commitment to quality post-sales support. Outsell Inc., an independent analyst and advisory firm, ranked Reprints Desk #1 in the most recent Document Delivery Vendor Scorecard.

About Derycz Scientific®
Derycz Scientific, Inc. develops companies, products, services and systems that facilitate the re-use of published content in a manner that helps organizations achieve their marketing, communication and research goals effectively and in compliance with copyright law and regulatory rules.  Its subsidiary companies include Reprints Desk, Inc. and Techniques Appliqueés aux Arts Graphiques, S.p.A. (TAAG).  For more information, please visit www.deryczscientific.com.

Forward-Looking Statements
Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; the Company's success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K. The Company assumes no obligation to update the cautionary information in this release.